Alzheimer's disease

[1]  G. Savva,et al.  Epidemiological Studies of the Effect of Stroke on Incident Dementia: A Systematic Review , 2010, Stroke.

[2]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[3]  B. Hyman,et al.  Interaction of the Cytosolic Domains of sorLA/LR11 with the Amyloid Precursor Protein (APP) and β-Secretase β-Site APP-Cleaving Enzyme , 2006, The Journal of Neuroscience.

[4]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[5]  K. Blennow,et al.  Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial , 2008, The Lancet Neurology.

[6]  J. Pariente,et al.  Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve , 2009, Brain : a journal of neurology.

[7]  K. Rockwood,et al.  Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial. , 1996, Neuroepidemiology.

[8]  L. Schneider,et al.  Memantine for dementia. , 2006, The Cochrane database of systematic reviews.

[9]  M. Owen,et al.  Glycogen synthase kinase‐3β and tau genes interact in Alzheimer's disease , 2008, Annals of neurology.

[10]  A. LaCroix,et al.  Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. , 2003, JAMA.

[11]  Jesús Avila,et al.  The role of GSK3 in Alzheimer disease , 2009, Brain Research Bulletin.

[12]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[13]  Agneta Nordberg,et al.  PET imaging of amyloid in Alzheimer's disease , 2004, The Lancet Neurology.

[14]  C. Lyketsos,et al.  Management of agitation and aggression associated with Alzheimer disease , 2009, Nature Reviews Neurology.

[15]  Peter J. Snyder,et al.  Immediate and delayed effects of cognitive interventions in healthy elderly: A review of current literature and future directions , 2009, Alzheimer's & Dementia.

[16]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[17]  P. Tariot,et al.  Neuroprotective properties of valproate , 2002, Journal of Molecular Neuroscience.

[18]  C. Ballard,et al.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial , 2009, The Lancet Neurology.

[19]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[20]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[21]  P Julin,et al.  Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study , 2000, Journal of neurology, neurosurgery, and psychiatry.

[22]  Perminder Sachdev,et al.  Can cognitive exercise prevent the onset of dementia? Systematic review of randomized clinical trials with longitudinal follow-up. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[23]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[24]  M G McInnis,et al.  Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. , 2000, Science.

[25]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[26]  B. McGuinness,et al.  Systematic review: blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[27]  G. Samsa,et al.  Alzheimer disease: operating characteristics of PET--a meta-analysis. , 2004, Radiology.

[28]  S. Iliffe,et al.  service Topic collections Notes , 2022 .

[29]  N. Ertekin-Taner.  Genetics of Alzheimer disease in the pre- and post-GWAS era , 2010, Alzheimer's Research & Therapy.

[30]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[31]  J. Wegiel,et al.  Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  L. Nyberg,et al.  Increased risk of dementia following mild head injury for carriers but not for non-carriers of the APOE ε4 allele , 2006, International Psychogeriatrics.

[33]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[34]  P. Crane,et al.  Antioxidant Vitamin Supplement Use and Risk of Dementia or Alzheimer's Disease in Older Adults , 2008, Journal of the American Geriatrics Society.

[35]  A. Roses.  An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. , 2010, Archives of neurology.

[36]  R. Mohs,et al.  Cerebral infarcts in patients with autopsy-proven Alzheimer's disease , 1998, Neurology.

[37]  A. Nordberg,et al.  Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease , 2010, Brain : a journal of neurology.

[38]  H. Engler,et al.  High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. , 2009, Current Alzheimer research.

[39]  J. Hardy,et al.  Has the amyloid cascade hypothesis for Alzheimer's disease been proved? , 2006, Current Alzheimer research.

[40]  Nick C Fox,et al.  Imaging cerebral atrophy: normal ageing to Alzheimer's disease , 2004, The Lancet.

[41]  S. Fay,et al.  Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial , 2006, Canadian Medical Association Journal.

[42]  B T Hyman,et al.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. , 2000, The American journal of pathology.

[43]  C. Ballard,et al.  Quantification of Alzheimer pathology in ageing and dementia: age‐related accumulation of amyloid‐β(42) peptide in vascular dementia , 2006, Neuropathology and applied neurobiology.

[44]  I. McKeith,et al.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.

[45]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[46]  Elizabeth Beattie,et al.  Cognitive training for early-stage Alzheimer's disease and dementia. , 2009, Journal of gerontological nursing.

[47]  M. Meraz-Ríos,et al.  Tau oligomers and aggregation in Alzheimer’s disease , 2010, Journal of neurochemistry.

[48]  D. Thakker,et al.  Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice , 2009, Proceedings of the National Academy of Sciences.

[49]  Yaakov Stern,et al.  Mediterranean diet and risk for Alzheimer's disease , 2006, Annals of neurology.

[50]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[51]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[52]  J. Becker,et al.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[53]  A. Simmons,et al.  AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.

[54]  J. Johansson,et al.  Amino acid sequence determinants and molecular chaperones in amyloid fibril formation. , 2010, Biochemical and biophysical research communications.

[55]  C. Ballard,et al.  Neuroleptic drugs in dementia: benefits and harm , 2006, Nature Reviews Neuroscience.

[56]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[57]  Frederik Barkhof,et al.  Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion , 2002, The Lancet Neurology.

[58]  P. Scheltens,et al.  Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline , 2007, European journal of neurology.

[59]  A. Myers,et al.  Problems and Solutions in the Genetic Analysis of Late-Onset Alzheimer’s Disease , 2004, Neurodegenerative Diseases.

[60]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[61]  Henry Brodaty,et al.  Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial , 2009, The Lancet Neurology.

[62]  Nick C. Fox,et al.  A meta-analysis of hippocampal atrophy rates in Alzheimer's disease , 2009, Neurobiology of Aging.

[63]  M. Kivipelto,et al.  Cholesterol as a risk factor for Alzheimer's disease – epidemiological evidence , 2006, Acta neurologica Scandinavica. Supplementum.

[64]  R. Wade-Martins,et al.  Functional MAPT haplotypes: Bridging the gap between genotype and neuropathology , 2007, Neurobiology of Disease.

[65]  Nancy L Pedersen,et al.  Reaching the limits of genome-wide significance in Alzheimer disease: back to the environment. , 2010, JAMA.

[66]  S. Gauthier,et al.  Alzhemed: a potential treatment for Alzheimer's disease. , 2007, Current Alzheimer research.

[67]  Alexander Libin,et al.  Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[68]  Klaus P. Ebmeier,et al.  Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[69]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[70]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[71]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[72]  H. Beydoun,et al.  Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta‐analysis , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[73]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[74]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[75]  Michael Weiner,et al.  Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection , 2010, NeuroImage.

[76]  J. O'Brien,et al.  Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities , 2002, International journal of geriatric psychiatry.

[77]  I. McKeith,et al.  Epidemiological Pathology of Dementia: Attributable-Risks at Death in the Medical Research Council Cognitive Function and Ageing Study , 2009, PLoS medicine.

[78]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[79]  K. Sink,et al.  Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. , 2009, JAMA.

[80]  C. Ballard,et al.  Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. , 2008, The Journal of clinical psychiatry.

[81]  D. Foley,et al.  Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study. , 2004, American journal of epidemiology.

[82]  L. Schneider,et al.  Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[83]  J. Weber,et al.  Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. , 1992, Science.

[84]  Robert Howard,et al.  Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial , 2006, BMJ : British Medical Journal.

[85]  D. Na,et al.  Systematic review of health behavioral risks and cognitive health in older adults , 2009, International Psychogeriatrics.

[86]  T. Uema,et al.  The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. , 2007, Human molecular genetics.

[87]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[88]  B. Winblad,et al.  The age-dependent relation of blood pressure to cognitive function and dementia , 2005, The Lancet Neurology.

[89]  H. Kuo,et al.  Diabetes and the Risk of Multi-System Aging Phenotypes: A Systematic Review and Meta-Analysis , 2009, PloS one.

[90]  M. Hamer,et al.  Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence , 2008, Psychological Medicine.

[91]  K. Blennow,et al.  CSF Biomarkers , 2009, Annals of the New York Academy of Sciences.

[92]  Nick C Fox,et al.  Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42 , 2010, Annals of neurology.

[93]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[94]  K. Lunetta,et al.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.

[95]  Jessica A. Grahn,et al.  Putting brain training to the test , 2010, Nature.

[96]  A M Pittman,et al.  The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. , 2005, Human molecular genetics.

[97]  S. Gauthier,et al.  Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis , 2008, International journal of geriatric psychiatry.

[98]  S. Love,et al.  Angiotensin‐converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE‐1 to cerebral amyloid angiopathy , 2008, Neuropathology and applied neurobiology.

[99]  A. Lees,et al.  Neurofibrillary tangle parkinsonian disorders—tau pathology and tau genetics , 1999, Movement disorders : official journal of the Movement Disorder Society.

[100]  P. Sachdev,et al.  Brain reserve and dementia: a systematic review , 2005, Psychological Medicine.

[101]  C. Brayne,et al.  Dementia risk prediction in the population: are screening models accurate? , 2010, Nature Reviews Neurology.

[102]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[103]  Johannes Kornhuber,et al.  Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease , 2009, Journal of Neural Transmission.

[104]  K. Anstey,et al.  Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[105]  B. Winblad,et al.  An active and socially integrated lifestyle in late life might protect against dementia , 2004, The Lancet Neurology.

[106]  Bengt Långström,et al.  [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients , 2009, Neurochemistry International.

[107]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[108]  A. Mackinnon,et al.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.

[109]  H. Wiśniewski,et al.  High levels of amyloid-beta protein from S182 (Glu246) familial Alzheimer's cells. , 1995, Neuroreport.

[110]  A. Roses,et al.  Genetic variation at a single locus and age of onset for Alzheimer's disease , 2010, Alzheimer's & Dementia.